NCT05811481

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

Clinical Research and Laboratory Animal Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 192 (estimated)
• Sponsor: WenBo Guo · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2. To evaluate the safety and prognostic imaging factors of regorofenib in advanced second-line therapy; 3, to explore whether it is necessary to increase the treatment of TACE in the second-line treatment of advanced HCC.

Conditions

• Hepatocellular Carcinoma
• Transcatheter Arterial ChEmoembolization
• Regorafenib

Interventions

Type	Name	Description
PROCEDURE	TACE	Transcatheter Arterial Chemoembolization
DRUG	Regorafenib	Regorafenib alone

Timeline

• Start date: 2022-12-27
• Primary completion: 2024-12-27
• Completion: 2025-12-27
• First posted: 2023-04-13
• Last updated: 2023-04-13

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study